Advanced

Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin coated beads.

Faust, Helena LU ; Knekt, Paul; Forslund, Ola LU and Dillner, Joakim LU (2010) In Journal of General Virology 91. p.1840-1848
Abstract
We developed and validated a high-throughput human papillomavirus (HPV) serology method based on Luminex technology, using pseudovirions (PsVs) of eight mucosal HPV types (HPV 6, 11, 16, 18, 31, 45, 52 and 58) and two cutaneous HPV types (HPV 5 and 38) bound to heparin coated beads. Analysis with neutralising type-specific monoclonal antibodies against included HPV types indicated type-specificity of the assay. Analysis of negative control serum samples from 63 children and 71 middle-aged women with up to one lifetime sexual partner indicated high specificity. Positive control serum samples from subjects with known HPV DNA status or clinical diagnosis found expected sensitivities for most of the HPV types in 219 European serum samples, but... (More)
We developed and validated a high-throughput human papillomavirus (HPV) serology method based on Luminex technology, using pseudovirions (PsVs) of eight mucosal HPV types (HPV 6, 11, 16, 18, 31, 45, 52 and 58) and two cutaneous HPV types (HPV 5 and 38) bound to heparin coated beads. Analysis with neutralising type-specific monoclonal antibodies against included HPV types indicated type-specificity of the assay. Analysis of negative control serum samples from 63 children and 71 middle-aged women with up to one lifetime sexual partner indicated high specificity. Positive control serum samples from subjects with known HPV DNA status or clinical diagnosis found expected sensitivities for most of the HPV types in 219 European serum samples, but less than expected in 124 samples from Africa. HPV 45 and 52 did not react as expected with the human serum samples. The Pseudovirion-Luminex method was used to determine the HPV-seropositivity-associated relative risk for future cervical cancer using 208 serum samples from a prospective study of 18814 women followed for 23 years, previously analysed with standard HPV 16 ELISA. The Pseudovirion-Luminex method gave similar results as ELISA (Kappa= 0.77). As expected, HPV seropositivities assayed using the Pseudovirion-Luminex method found increased risk for cervical cancer for HPV 16 (OR=7.7, CI 95%=2.6-23) and HPV 31(OR=4.1, CI 95%=1.6-10.8), non-significant tendencies for increased risk for other mucosal HPV types and no risk for the cutaneous HPV types. In summary, multiplexed HPV serology using mammalian-derived pseudovirions selected for native conformation by binding to heparin-coated beads is validated as a high-throughput HPV serological method, for most of the analysed HPV types. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of General Virology
volume
91
pages
1840 - 1848
publisher
Society for General Microbiology
external identifiers
  • wos:000279747600024
  • pmid:20181747
  • scopus:77954157567
ISSN
1465-2099
DOI
10.1099/vir.0.019349-0
language
English
LU publication?
yes
id
a06a34fa-9c38-4a66-ac54-428a56ce0873 (old id 1582921)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20181747?dopt=Abstract
date added to LUP
2010-04-06 11:09:46
date last changed
2018-08-12 03:09:20
@article{a06a34fa-9c38-4a66-ac54-428a56ce0873,
  abstract     = {We developed and validated a high-throughput human papillomavirus (HPV) serology method based on Luminex technology, using pseudovirions (PsVs) of eight mucosal HPV types (HPV 6, 11, 16, 18, 31, 45, 52 and 58) and two cutaneous HPV types (HPV 5 and 38) bound to heparin coated beads. Analysis with neutralising type-specific monoclonal antibodies against included HPV types indicated type-specificity of the assay. Analysis of negative control serum samples from 63 children and 71 middle-aged women with up to one lifetime sexual partner indicated high specificity. Positive control serum samples from subjects with known HPV DNA status or clinical diagnosis found expected sensitivities for most of the HPV types in 219 European serum samples, but less than expected in 124 samples from Africa. HPV 45 and 52 did not react as expected with the human serum samples. The Pseudovirion-Luminex method was used to determine the HPV-seropositivity-associated relative risk for future cervical cancer using 208 serum samples from a prospective study of 18814 women followed for 23 years, previously analysed with standard HPV 16 ELISA. The Pseudovirion-Luminex method gave similar results as ELISA (Kappa= 0.77). As expected, HPV seropositivities assayed using the Pseudovirion-Luminex method found increased risk for cervical cancer for HPV 16 (OR=7.7, CI 95%=2.6-23) and HPV 31(OR=4.1, CI 95%=1.6-10.8), non-significant tendencies for increased risk for other mucosal HPV types and no risk for the cutaneous HPV types. In summary, multiplexed HPV serology using mammalian-derived pseudovirions selected for native conformation by binding to heparin-coated beads is validated as a high-throughput HPV serological method, for most of the analysed HPV types.},
  author       = {Faust, Helena and Knekt, Paul and Forslund, Ola and Dillner, Joakim},
  issn         = {1465-2099},
  language     = {eng},
  pages        = {1840--1848},
  publisher    = {Society for General Microbiology},
  series       = {Journal of General Virology},
  title        = {Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin coated beads.},
  url          = {http://dx.doi.org/10.1099/vir.0.019349-0},
  volume       = {91},
  year         = {2010},
}